公开(公告)号：US20160139137A1

公开(公告)日：2016-05-19

申请号：US14900133

申请日：2014-06-23

Applicant: FUNDACIÓ INSTITUT CATALÀ D'INVESTIGACIÓ QUÍMICA (ICIQ) ,  INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS

Inventor： Emilio PALOMARES ,  Georgiana STOICA ,  Iván CASTELLÓ SERRANO

IPC: G01N33/58 ,  C12Q1/37

CPC classification number: G01N33/588 ,  C09K11/02 ,  C09K11/025 ,  C09K11/883 ,  C12Q1/34 ,  C12Q1/37 ,  G01N2333/914 ,  G01N2333/976 ,  G01N2458/00 ,  G01N2800/382

Abstract: The invention refers to a nanoparticle comprising (i) a core comprising a first population of quantum dots (QDs) embedded in silica, (ii) a shell comprising a second population of QDs embedded in silica, (iii) at least one biomolecule selected from a peptide, a nucleic acid, a carbohydrate or a lipid which comprises a cleavage site that is susceptible of being cleaved by a hydrolytic enzyme, said biomolecule being bound to the surface of the shell through a moiety, and (iv) a photoluminescent label for each biomolecule, wherein the label is bound to the part of the biomolecule which detaches from the nanoparticle after cleavage of said biomolecule by a hydrolytic enzyme, wherein the first and second QD populations have different maximum photoluminescence emission wavelengths, and only the second QD population is susceptible of producing Forster resonance energy transfer (FRET) with the photoluminescent label.

Abstract translation: 本发明涉及一种纳米颗粒，其包含（i）包含嵌入二氧化硅中的第一批量子点（QD）的核心，（ii）包含埋在二氧化硅中的第二组质子数量的壳体，（iii）至少一种选自以下的生物分子： 肽，核酸，碳水化合物或脂质，其包含易于被水解酶切割的切割位点，所述生物分子通过部分结合到壳的表面，和（iv）光致发光标记，用于 每个生物分子，其中所述标记与所述生物分子的部分结合，所述部分在通过水解酶切割所述生物分子之后与所述纳米颗粒分离，其中所述第一和第二QD群体具有不同的最大光致发光发射波长，并且仅第二QD群体 容易产生与光致发光标签的福斯特共振能量转移（FRET）。

公开(公告)号：US09341627B2

公开(公告)日：2016-05-17

申请号：US13202131

申请日：2010-02-19

Applicant: Sunyoung Kim

Inventor： Sunyoung Kim

IPC: G01N33/574 ,  C12Q1/68 ,  A61B5/00

CPC classification number: C12Q1/34 ,  A61B5/0059 ,  A61K31/198 ,  A61K31/505 ,  A61K31/506 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/574 ,  G01N2333/914 ,  G01N2500/04 ,  G01N2800/52

Abstract: A rapid, infrared spectroscopic method has been developed to assess the efficacy of targeted chemotherapeutics against the structure of the polypeptide target, based on the effect of natural polymorphic sequence variation on the conformation of the protein. This method has an advantage over the current genomics-based screening, as the new method provides a direct readout of the structural, and hence functional, outcome of polymorphisms to the protein region targeted by drugs. It allows rapid measurement of a protein's susceptibility to therapeutic targeted agents, prior to using the drug as treatment in the patient. This method can be used to identify biomarkers for a response for a protein to a drug which can be readily tested, interpreted, and used in a clinical setting.

Abstract translation: 基于天然多态性序列变异对蛋白质构象的影响，开发了一种快速的红外光谱方法，以评估靶向化学治疗剂对多肽靶结构的功效。 该方法相对于目前基于基因组学的筛选具有优势，因为新方法提供了针对药物的蛋白质区域的多态性的结构，从而功能性的结果的直接读出。 在使用药物作为患者的治疗之前，它可以快速测量蛋白质对治疗性靶向药物的敏感性。 该方法可用于鉴定蛋白质对药物的响应的生物标志物，其可以容易地在临床环境中测试，解释和使用。

公开(公告)号：US20160123983A1

公开(公告)日：2016-05-05

申请号：US14851471

申请日：2015-09-11

Applicant: Abbott Laboratories

Inventor： GEORGE J. DAWSON ,  Suresh M. Desai ,  Robin A. Gutierrez ,  A. Scott Muerhoff ,  John Prostko

IPC: G01N33/576

CPC classification number: G01N33/5767 ,  G01N33/5306 ,  G01N33/54306 ,  G01N33/56983 ,  G01N2333/186 ,  G01N2333/914 ,  G01N2469/10 ,  G01N2469/20

Abstract: The present invention generally relates to combination immunoassays, reagents and kits for simultaneous detection of HCV antigens and anti-HCV antibodies in a test sample.

Abstract translation: 本发明一般涉及用于在测试样品中同时检测HCV抗原和抗HCV抗体的组合免疫测定，试剂和试剂盒。

公开(公告)号：US20160015702A1

公开(公告)日：2016-01-21

申请号：US14424595

申请日：2013-08-27

Applicant: CeMM - Forschungszentrum für Molekulare Medizin GmbH

Inventor： Kilian HUBER ,  Giulio SUPERTI-FURGA

IPC: A61K31/4545 ,  G01N33/50 ,  G01N33/94 ,  A61K45/06

CPC classification number: A61K31/4545 ,  A61K45/06 ,  G01N33/5011 ,  G01N33/573 ,  G01N33/94 ,  G01N2333/4704 ,  G01N2333/914 ,  G01N2430/00 ,  G01N2500/04 ,  G01N2800/52

Abstract: The present invention relates to an (S)-enantiomer of an aminoheteroaryl compound for use in treating and/or preventing cancer in a subject. The invention further relates to a pharmaceutical composition comprising said compound. Another aspect of the invention is directed to an in vitro method for determining the effectiveness of said (S)-enantiomer of an aminoheteroaryl compound, or said pharmaceutical composition, the method comprising the steps of: (a) obtaining a cell or tissue sample from a subject; and (b) determining the subject's NUDT1/MTH1-status; wherein a NUDT1/MTH1-positive cell or tissue sample is indicative of an effective treatment and/or prevention of cancer. In addition, provided herein is a screening method for identifying a target of an (S)-enantiomer of an aminoheteroaryl compound. Furthermore, in context of this invention, the herein described compounds inhibit the biological activity of MTH1.

Abstract translation: 本发明涉及用于治疗和/或预防受试者癌症的氨基杂芳基化合物的（S） - 对映异构体。 本发明还涉及包含所述化合物的药物组合物。 本发明的另一方面涉及用于测定氨基杂芳基化合物或所述药物组合物的所述（S） - 对映异构体的有效性的体外方法，所述方法包括以下步骤：（a）获得细胞或组织样品， 课程; 和（b）确定受试者的NUDT1 / MTH1状态; 其中NUDT1 / MTH1阳性细胞或组织样品指示有效治疗和/或预防癌症。 此外，本文提供了用于鉴定氨基杂芳基化合物的（S） - 对映异构体的靶标的筛选方法。 此外，在本发明的上下文中，本文所述的化合物抑制MTH1的生物活性。

公开(公告)号：US20150338410A1

公开(公告)日：2015-11-26

申请号：US14729498

申请日：2015-06-03

Applicant: Shire Human Genetic Therapies, Inc.

Inventor： Daniel S. Roseman

IPC: G01N33/573

CPC classification number: G01N33/573 ,  G01N2333/42 ,  G01N2333/914 ,  G01N2333/916 ,  G01N2400/10

Abstract: Disclosed herein are methods and kits which are useful for detecting presence of an enzyme and the relative amount of glycan associated with the enzyme in a test sample based upon the enzyme's ability to competitively inhibit the binding of a ligand in such test sample. The present invention provides the ability to evaluate cell culture conditions and optimize the desired glycoform content of recombinantly prepared enzymes.

Abstract translation: 本文公开了可用于检测酶的存在和测试样品中与酶相关的聚糖的相对量的方法和试剂盒，其基于酶在竞争性抑制配体在该测试样品中结合的能力。 本发明提供了评估细胞培养条件并优化重组制备的酶的所需糖型含量的能力。

公开(公告)号：US20150219624A1

公开(公告)日：2015-08-06

申请号：US14693832

申请日：2015-04-22

Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER

Inventor： Hans-Guido WENDEL ,  Andrew Wolfe ,  Kamini Sing ,  Yi Zhong ,  Phillip Drewe

IPC: G01N33/50 ,  G01N33/574 ,  A61K31/429 ,  A61K31/357 ,  A61K31/58

CPC classification number: G01N33/5011 ,  A61K31/343 ,  A61K31/357 ,  A61K31/429 ,  A61K31/58 ,  G01N33/57496 ,  G01N33/582 ,  G01N2333/4703 ,  G01N2333/914 ,  G01N2500/02 ,  G01N2500/10 ,  G01N2800/52

Abstract: Methods are provided for identifying agents capable of modulating cap-dependent RNA translation by comparing translation efficiency in the presence and absence of the agent in an in-vitro or in-vivo translation system that comprises eIF4A and an mRNA having one or more eIF4A-dependent translation-controlling motifs. The modulation of translation in the presence of the agent indicates the agent as capable of modulating cap-dependent mRNA translation. The method can be used to identify anti-cancer agents and oncogenes that may be responsible for tumorigenesis.

Abstract translation: 提供了通过比较包含eIF4A和具有一个或多个eIF4A依赖性的mRNA的体外或体内翻译系统中存在和不存在试剂的翻译效率来鉴定能够调节帽依赖性RNA翻译的方法的方法 翻译控制图案。 在试剂存在下调节翻译表明该试剂能够调节帽依赖性mRNA翻译。 该方法可用于鉴定可能导致肿瘤发生的抗癌剂和致癌基因。

公开(公告)号：US09075057B2

公开(公告)日：2015-07-07

申请号：US14124979

申请日：2012-06-08

Applicant: Daniel S. Roseman

Inventor： Daniel S. Roseman

IPC: G01N33/53 ,  G01N33/573

CPC classification number: G01N33/573 ,  G01N2333/42 ,  G01N2333/914 ,  G01N2333/916 ,  G01N2400/10

Abstract: Disclosed herein are methods and kits which are useful for detecting presence of an enzyme and the relative amount of glycan associated with the enzyme in a test sample based upon the enzyme's ability to competitively inhibit the binding of a ligand in such test sample. The present invention provides the ability to evaluate cell culture conditions and optimize the desired glycoform content of recombinantly prepared enzymes.

Abstract translation: 本文公开了可用于检测酶的存在和测试样品中与酶相关的聚糖的相对量的方法和试剂盒，其基于酶在竞争性抑制配体在该测试样品中结合的能力。 本发明提供了评估细胞培养条件并优化重组制备的酶的所需糖型含量的能力。

公开(公告)号：US20150118686A1

公开(公告)日：2015-04-30

申请号：US14534427

申请日：2014-11-06

Applicant: Shiseido Company, Ltd.

Inventor： TOSHIHIKO HIBINO ,  YAYOI KAMATA ,  MAMI YAMAMOTO

IPC: C12Q1/68 ,  G01N33/573

CPC classification number: C12Q1/6883 ,  C12Q1/37 ,  C12Q2600/158 ,  G01N33/573 ,  G01N33/6881 ,  G01N2333/914 ,  G01N2333/96466 ,  G01N2500/04 ,  G01N2500/10 ,  G01N2800/202

Abstract: The present invention provides a method for screening and evaluating ameliorants of dry skin caused by atopic dermatitis, comprising: evaluating a candidate drug as being an ameliorant of dry skin caused by atopic dermatitis in the case the candidate drug significantly increases expression and/or activity of bleomycin hydrolase in comparison with a control drug.

Abstract translation: 本发明提供了筛选和评价由特应性皮炎引起的干性皮肤变性的方法，其包括：在候选药物显着增加表型和/或活性的情况下，将候选药物评估为由特应性皮炎引起的干性皮肤的改善剂 博来霉素水解酶与对照药相比。

公开(公告)号：US20150111786A1

公开(公告)日：2015-04-23

申请号：US14591678

申请日：2015-01-07

Applicant: DANA-FARBER CANCER INSTITUTE, INC.

Inventor： David Pellman

IPC: G01N33/50

CPC classification number: G01N33/5011 ,  A61K31/7088 ,  A61K31/7105 ,  G01N33/5026 ,  G01N33/57496 ,  G01N2333/914 ,  G01N2500/02 ,  G01N2500/04 ,  G01N2500/10

Abstract: The invention provides methods of treating a meiotic kinase-associated disease, preferably the meiotic kinase HSET, by administering an inhibitor of the meiotic kinase. Preferably, the disease is associated with the presence of supernumerary centrosomes, such as cancer. Methods of inhibiting the growth of a tumor cell by contacting the cell with an inhibitor of a meiotic kinase, preferably HSET, are also provided. Screening methods for identifying inhibitors of the meiotic Kinase HSET are also provided. Methods of selecting subjects for treatment with an inhibitor of a meiotic kinase, such as HSET, are also provides.

Abstract translation: 本发明提供了通过施用减数分裂激酶的抑制剂来治疗减数分裂激酶相关疾病，优选减数分裂激酶HSET的方法。 优选地，该疾病与诸如癌症的数量中心体的存在相关。 还提供了通过使细胞与减数分裂激酶抑制剂（优选HSET）接触来抑制肿瘤细胞生长的方法。 还提供了用于鉴定减数分裂激酶HSET的抑制剂的筛选方法。 还提供了选择用减数分裂激酶抑制剂如HSET治疗的受试者的方法。

公开(公告)号：US20140370582A1

公开(公告)日：2014-12-18

申请号：US14473871

申请日：2014-08-29

Applicant: Caris MPI, Inc.

Inventor： Daniel D. Von Hoff ,  Robert J. Penny

IPC: G06F19/00 ,  G01N33/574

CPC classification number: G01N33/57488 ,  C12Q1/6883 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/574 ,  G01N33/6893 ,  G01N2333/71 ,  G01N2333/91205 ,  G01N2333/914 ,  G06F19/00 ,  G06F19/18 ,  G06F19/20 ,  G06F19/28 ,  G06F19/34 ,  G06F19/3481 ,  G16H15/00 ,  G16H50/20

Abstract: A system and method for determining individualized medical intervention for a particular disease state, and especially for cancers, that includes the molecular profiling of a biological sample from the patient, determining whether any molecular findings including one or more genes, one or more gene expressed proteins, one or more molecular mechanisms, and/or combinations of such exhibit a change in expression compared to a reference, and identifying a non-specific disease therapy or agent capable of interacting with the genes, gene expressed proteins, molecular mechanisms, or combinations of such molecular findings that exhibited a change in expression.

Abstract translation: 用于确定特定疾病状态，特别是癌症的个体化医疗干预的系统和方法，其包括来自患者的生物样品的分子谱图，确定是否包括一个或多个基因的任何分子发现，一种或多种基因表达的蛋白质 ，一种或多种分子机制和/或其组合与参考文献相比表现出变化，并且鉴定能够与基因相互作用的非特异性疾病治疗或试剂，基因表达的蛋白质，分子机制或组合 这种表达变化的分子发现。